ACN

Cuba will soon distribute a medication, only one of its kind in the world, to treat diabetic foot ulcers in all Angilology services in the country.
In statements to the press in Havana, the director of the Genetic Engineering and Biotechnology Center (CIGB) Doctor Luis Herrera underscored the advantages of the medication produced by his entity, known as Heberprot-P, which has been administered to more than 250 Cuban patients, with successful results and full response by 87 of the cases.

Doctor Ernesto Lopez, head of the CIGB commercial division, explained that Heberprot-P is and injectable formula that steps up the cicatrization of deep and complex ulcers, thus reducing the number of amputations.

Doctor Lopez said that the medication has been registered in Cuba and included in the basic medications program; it has been patented in South Africa, Australia and Singapore. The Cuban medication is also expected to be patented in Japan, the United States and in Europe.

There are 350, 000 diabetic patients in Cuba, 12,000 of whom may be suffering from diabetic foot ulcers, while the number of amputations could reach up to 1,800, the doctor explained.

With that in mind, said the specialist, Cuba is creating all conditions and training personnel to administer Heberprot-P throughout the country including primary medical attention. Doctor Perez added that the medication will be available to all patients suffering from diabetic food ulcers.

Heberprot-P, a medication produced by Cuban biotechnology, reduces the number of surgical operations, cicatrization time, possible complications like gangrene and infections, and avoids high costs derived from long-time hospitalization; it also improves quality of life and the functional recovery of patients.

Doctor Jorge Berlanga, also from the CIGB, explained that 85 percent of amputations can be prevented, while 70 percent of those surgeries are applied on patients suffering from diabetes, a disease affecting some 194 million people around the world.